Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : IAVI
Deal Size : Inapplicable
Deal Type : Inapplicable
IAVI, Biofabri Start IMAGINE Trial for Tuberculosis Vaccine Candidate MTBVAC
Details : MTBVAC is a live-attenuated vaccine candidate, derived from a human isolate of Mycobacterium tuberculosis. It is being evaluated to prevent active TB lung disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : IAVI
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Bharat Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Bharat Biotech Begins Clinical Trials of TB Vaccine on Adults in India
Details : Mtbvac, the spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis, which is under clinical development for the treatment of tuberculosis in adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
March 24, 2024
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Bharat Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Agreement
Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC
Details : Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Partnership
Details : This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, w...
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Live-Attenuated Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Details : Undisclosed
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
July 23, 2021
Lead Product(s) : Live-Attenuated Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 12, 2019
Lead Product(s) : Live-Attenuated Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates
Details : Undisclosed
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
May 24, 2018
Lead Product(s) : Live-Attenuated Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : South African Tuberculosis Vaccine Initiative | Universidad de Zaragoza | TuBerculosis Vaccine Initiative
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Live-Attenuated Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
April 06, 2016
Lead Product(s) : Live-Attenuated Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : South African Tuberculosis Vaccine Initiative | TuBerculosis Vaccine Initiative | Triclinium Clinical Trial Project Management (Pty) Ltd. | Universidad de Zaragoza
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Live-Attenuated Mycobacterium Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
December 17, 2013
Lead Product(s) : Live-Attenuated Mycobacterium Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative
Deal Size : Inapplicable
Deal Type : Inapplicable